NDA 010402 · Wyeth Pharms
Premarin
Estrogens, Conjugated · Injection · Estrogen
Last checked: Nov 19, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1956
Dec 18, 1956
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,166
241 Phase 3, 150 recruiting
FAERS reports
59,171
41,980 serious, 1,854 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. (See WARNINGS, Malignant Neoplasms, Endometrial cancer .) Cardiovascular Disorders and Probable Dementia Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Cardiovascular Disorders and Probable...
What it is approved for
From the label in effect May 30, 2025.
INDICATIONS AND USAGE Premarin Intravenous (conjugated estrogens, USP) for injection is indicated in the treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology. Premarin Intravenous is indicated for short-term use only, to provide a rapid and temporary increase in estrogen levels.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 1956 Original approval · Type 3 - New Dosage Form Other Important Information from FDA
1 products under this application
- PREMARIN · ESTROGENS, CONJUGATED 25MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Estrogens" as an intervention, any sponsor and status, largest first.
- Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph NodesPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433589 · 6,600 participants (planned) · Start Feb 2007 · Primary completion Mar 2020
Drug: anthracycline-based; docetaxel and capecitabine and 2 more · For: Breast Cancer
Sites: Amsterdam, Netherlands
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05952557 · 5,511 participants · Start Oct 5, 2023 · Primary completion Mar 4, 2030
Drug: Camizestrant; Tamoxifen and 4 more · For: Breast Cancer, Early Breast Cancer
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 661 sites in all
The Third Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT07421908 · 5,000 participants (planned) · Start Mar 1, 2025 · Primary completion Mar 1, 2030
Drug: Traditional Chinese medicine for tonifying the kidney · For: Intrauterine Adhesion
Sites: Changsha, China
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePivotal-lookingActive, not recruiting
Stemline Therapeutics, Inc.Industry
NCT06492616 · 4,556 participants · Start Sep 27, 2024 · Primary completion Aug 2029
Drug: Elacestrant; Anastrozole and 3 more · For: Breast Cancer
Sites: Daphne, Alabama; Chandler, Arizona; Gilbert, Arizona · 555 sites in all
- Trial of Perioperative Endocrine Therapy - Individualising CarePivotal-lookingActive, not recruiting
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT02338310 · 4,486 participants · Start Sep 2008 · Primary completion Apr 2024
Drug: Aromatase Inhibitors · For: Breast Cancer
Sites: Dundonald, United Kingdom; Slough, United Kingdom; Aylesbury, United Kingdom · 128 sites in all
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05774951 · 4,300 participants (planned) · Start Mar 31, 2023 · Primary completion Apr 20, 2027
Drug: Camizestrant; Tamoxifen and 3 more · For: Breast Cancer, Early Breast Cancer
Sites: Birmingham, Alabama; Dothan, Alabama; Anchorage, Alaska · 709 sites in all
- Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT01547741 · 4,242 participants · Start Apr 2012 · Primary completion May 31, 2022
Drug: Doxorubicin; Cyclophosphamide and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Phoenix, Arizona; Scottsdale, Arizona · 915 sites in all
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- breast cancer9,643
- breast cancer female8,869
- drug ineffective3,442
- nausea2,413
- headache2,369
- pain2,304
- fatigue2,284
- off label use2,231
- dizziness1,686
- breast cancer metastatic1,682
- dyspnoea1,661
- malaise1,616
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4,156 |
| 2005 | 3,642 |
| 2006 | 3,215 |
| 2007 | 1,686 |
| 2008 | 3,634 |
| 2009 | 5,174 |
| 2010 | 9,123 |
| 2011 | 2,685 |
| 2012 | 2,581 |
| 2013 | 2,149 |
| 2014 | 2,043 |
| 2015 | 2,431 |
| 2016 | 2,530 |
| 2017 | 1,975 |
| 2018 | 1,787 |
| 2019 | 2,160 |
| 2020 | 2,285 |
| 2021 | 1,520 |
| 2022 | 1,402 |
| 2023 | 1,079 |
| 2024 | 856 |
| 2025 | 641 |
| 2026 | 412 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Premarin* (Estrogens, Conjugated)
2024 spending
$255M
Beneficiaries
231,894
610,592 claims
Per beneficiary
$1,100
$10.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $298,132,949 |
| 2021 | $291,232,583 |
| 2022 | $281,548,605 |
| 2023 | $279,329,987 |
| 2024 | $254,990,018 |
Part B: Premarin (Estrogens, Conjugated) · HCPCS J1410
2024 spending
$28K
Beneficiaries
103
201 claims
Per beneficiary
$268
2024 ASP limit $377.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $29,611 |
| 2021 | $30,866 |
| 2022 | $50,419 |
| 2023 | $27,894 |
| 2024 | $27,593 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Estrogen Deficiency and the Origin of Obesity during Menopause.
Lizcano F, Guzmán G · Biomed Res Int 2014 · Systematic Review
- Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition.
Andy C, Nerattini M, Jett S, et al. · Front Endocrinol (Lausanne) 2024 · Meta-Analysis, Systematic Review
- Treatment of urge incontinence in postmenopausal women: A systematic review.
Bapir R, Bhatti KH, Eliwa A, et al. · Arch Ital Urol Androl 2023 · Meta-Analysis, Systematic Review
- Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.
Genazzani AR, Monteleone P, Giannini A, et al. · Hum Reprod Update 2021 · Randomized Controlled Trial
- [Premarin].
Lebech PE · Ugeskr Laeger 1976 · Clinical Trial
- Estrogen for schizophrenia.
Chua WL, de Izquierdo SA, Kulkarni J, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.